Remove 2022 Remove Compounding Remove Diabetes
article thumbnail

Hims & Hers Health to introduce generic Liraglutide in 2025 amid growing demand for weight-loss medications

Express Pharma

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. It results in less weight loss on average than Novo’s newer in-demand Wegovy, which launched in 2020 and was approved in 2022 for adolescents aged 12 and older.

article thumbnail

ASBM Statement on FDA Announcing End of 2-Year GLP-1 Shortage

Safe Biologics

On February 22nd, the US Food and Drug Administration (FDA) announced the resulution of a years-long shortage of semaglutide, the key ingredient in popular GLP-1 weight loss and diabetes medications Ozempic amd Wegovy. Both drugs have been on the FDAs drug shortage list since 2022. On a continuum of risk, U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends

Express Pharma

Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3 billion in 2023 and is expected to grow at a CAGR of 8.4 per cent from 2024 to 2030.

Diabetes 105
article thumbnail

Diabetes Drug Shortages and Fake Ozempic

National Association of Boards of Pharmacy

Injectable diabetes medications including semaglutide, namely Wegovy and Ozempic, have been in shortage since 2022 , limiting patient access to the drug across the nation. Simultaneously, compounding pharmacies have been overwhelmed with the production of semaglutide injections that are compounded copies of Ozempic and Wegovy.

article thumbnail

Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2

pharmaphorum

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The post Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2 appeared first on.

article thumbnail

The future of diagnosing and monitoring NAFLD/NASH could be noninvasive

Pharmaceutical Technology

The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) continues to increase, compounded by risk factors such as advanced age, obesity, ethnicity, and type 2 diabetes mellitus (T2DM). 2022; Zeng et al., Available at: [link] alcoholic_fatty_liver.7.aspx and Sebastiani, G.

article thumbnail

OrsoBio Reports the First Patient Dosing of TLC-3595 in P-IIa Clinical Trial for the Treatment of Type 2 Diabetes

PharmaShots

biomarker of glycemic control, fatty acid oxidation, lipids, and MRI/MRS-based assessments of muscle and liver fat OrsoBio obtained an exclusive global right in 2022 to an ACC2 inhibitor program with lead compound TLC-3595 from Shionogi & Co., of therapy while additional exploratory EPs incl.